Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (29)	2/13/2002 12:04:33 PM
From: nigel bates	Respond to of 197

Cheers, Mike. Some interesting stuff there - "...2:50 Yeast Display for Affinity Maturation of Human Fab Antibodies Dr. Simon E. Hufton, Director of Research, Dyax SA The rapid and efficient affinity maturation of biomolecules is a critical component of the drug development pipeline. Selection of yeast-displayed repertoires by fluorescent-activated cell sorting has proven an effective method for the affinity maturation of scFv antibodies. We present the affinity maturation of human Fab antibodies by similar selection of yeast-displayed repertoires. Furthermore, the use of the yeast mating life cycle to generate combinatorial diversity will be presented, and application to both affinity maturation and the generation of large naïve antibody repertoires will be discussed..."